AstraZeneca

AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com.

AstraZeneca RSS Channel

Title Filter      Display #  
# Article Title
1 Positive results from Phase IIb benralizumab study in severe asthma
2 MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory
3 AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease
4 AstraZeneca and Redx Pharma agree research collaboration
5 New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
6 United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
7 AstraZeneca agrees strategic transaction with Almirall in respiratory disease
8 MedImmune and Advaxis partner on immuno-oncology combination clinical trial
9 AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
10 AstraZeneca and Max Planck Institute announce research agreement
11 AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
12 Clarification regarding Pfizer statement
13 MedImmune and Incyte announce collaboration on immuno-oncology combination clinical trial
14 AstraZeneca Board rejects Pfizer proposal
15 AstraZeneca and MRC enter strategic collaboration
16 MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
17 FDA Advisory Committee votes on investigational medicine metreleptin
18 AstraZeneca to invest £120 million in new manufacturing facility to produce Zoladex
19 AstraZeneca advances MedImmune's benralizumab to Phase III in severe asthma
20 AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]